News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Japan's banks warn AI-enabled cyberattacks could disrupt services
A Japanese banking lobby group has flagged risk of service disruptions from AI-powered cyberattacks. Financial institutions are assessing preparedness ahead of potential threats.
Macron pushes G7 to widen access to Anthropic's Mythos AI model
French president signals diplomatic effort to expand availability of Anthropic's latest model beyond current constraints. Details on G7 coordination and timeline remain unclear.
Kirkland's $500M AI Play Hinges on Data Work, Not Tools
Kirkland & Ellis is spending $500M on AI with Palantir, but the real bet is organizing decades of firm knowledge. Whether it pays off depends on lawyer incentives and data maintenance, not software.
Crosby Benchmarks AI Contract Negotiation; ChatGPT 5.5 Scores 50.5%
Crosby's new Multi-turn Negotiation Bench tests how frontier models handle multi-step contract redlining. ChatGPT 5.5 led; all models lagged behind human lawyers on finding alternative deal terms.
Ironclad and Legora Connect Their Legal AIs in Bidirectional Integration
Ironclad, the contract lifecycle platform, is linking its AI to Legora's legal research engine so in-house teams can analyze contracts against regulatory changes without leaving either system. Phased rollout begins this year.
Law Firms Now Train Custom AI Models on Their Own Workflows
Harvey, Kirkland & Ellis, and Thomson Reuters are fine-tuning open source LLMs on firm-specific data to automate complex legal work. Here's why the old strategy is back.
Perplexity Enters Legal Market With Hallucination-First Pitch
Perplexity is hosting 'Computer for Counsel' in New York next week to announce legal connectors and premium sources. Five Big Tech players now compete in legal AI, reshaping a traditionally insular market.
Crosby Law Firm Builds AI Practice on Fixed Fees and Lawyer Judgment
Crosby co-founder Ryan Daniels explains how an MSO model aligns incentives to deploy AI agents alongside experienced lawyers—and why the firm sometimes accepts losses to prove the model works.
Insilico's AI-Designed Drug Reaches First Human Trial
Insilico Medicine dosed the first patient with ISM8969, an NLRP3 inhibitor designed using AI. The Phase I study marks a clinical validation of AI-driven drug discovery in a real patient.
Abarca Health and LucyRx merge to build PBM for commercial and government
Abarca Health and LucyRx announced a strategic combination to create a pharmacy benefit manager serving both commercial and government markets. Details on deal terms and timing remain undisclosed.
$65B pharma M&A quarter signals patent cliff panic
US pharma deal value hit $65 billion in Q1 2026, the strongest quarter since 2020, as companies race to fill pipelines ahead of massive patent expirations. Here's what's driving the surge.
Turbine's Virtual Lab finds hidden cancer targets DepMap misses
Turbine screened 30,000 perturbation combinations to identify eight biomarker candidates for PARP inhibitor resistance. Two are now in clinical trials—including one unknown to DepMap alone.